Table 5.
Main characteristics of published studies on adenomyosis, endometriosis, and pregnancy outcomes.
| Study design | Number of patients | Treatment protocols and IVF characteristics | CPR | LBR | Authors/year | |||
|---|---|---|---|---|---|---|---|---|
| Adenomyosis | Control | Adenomyosis | Control | Adenomyosis | Control | |||
| Retrospective cohort study | 20 | 54 | Long-term (> 3 months) GnRH agonist prior to first IVF/ICSI cycle | 35% | 30% | Mijatovic et al., 20109 | ||
| Retrospective cohort study | 37 | 164 | Only fresh ET | 35% | 31% | 29.7% (OGR) | 29.3% (OGR) | Costello et al., 201116 |
| Retrospective cohort study | 38 | 137 | Only D4/5 fresh ET | 23.6% | 43.6% | Thalluri et al., 201223 | ||
| Prospective multicenter | 49 | 49 | Only asymptomatic Adenomyosis patients with fresh ET | 43% | 29% | 35% | 18% | Benaglia et al., 201417 |
| Retrospective cohort study | 34 | 137 | All patients underwent PGS, 79.4% (n = 27) adenomyosis underwent ultra-long GnRH-agonist down regulation | 47% | 80% | Stanekova et al., 201815 | ||
| Prospective multicenter cohort study |
120 (fresh) 79 (FET) |
335 (fresh) 170 (FET) |
23.1% (fresh) 40.5% (FET) |
35.6% (fresh) 40.0% (FET) |
11.5% (fresh) 24.1% (FET) |
17.0% (fresh) 23.5% (FET) |
Higgins et al., 202122 | |
| Retrospective matched cohort study | Adenomyosis/endometriosis/ control: 328/242/331 | All received oocytes donation | Adenomyosis/endometriosis/ control: 40%/44%/30.8% | Adenomyosis/endometriosis/ control: 26.8%/38%/37.1% | Martinez-Conejero et al., 201121 | |||
| Retrospective study |
Adenomyosis: Fresh ET without GnRH-a pretreatment/ Fresh ET with GnRH-a pretreatment /FET with GnRH-a Pretreatment: 147/105/43 |
Fresh ET without GnRH-a pretreatment/ Fresh ET with GnRH-a pretreatment /FET with GnRH-a Pretreatment: 25.2%/30.5%/39.5% |
Park et al., 201610 | |||||
| Retrospective cohort study | Adenomyosis/endometriosis/adenomyosis + endometriosis/control: 64/88/355/466 | Adenomyosis group underwent ultra-long down regulation, All D2 or D3 ET | Adenomyosis/endometriosis/ adenomyosis + endometriosis/control: 23.44%/36.55%/22.72%/35.55% | Adenomyosis/endometriosis/adenomyosis + endometriosis/control: 12.5%/26.48%/11.36%/27.47% | Sharma et al., 201911 | |||
| Retrospective cohort study |
Adenomyosis FET pretreatment/without pretreatment: 48/140 Cumulative LBR group Pretreatment/without pretreatment: 97/216 |
All adenomyosis patients, GnRH agonist pretreatment at early follicle phase up to 3 doses |
Adenomyosis FET pretreatment/without pretreatment: 37.7%/21.2% Cumulative LBR group Pretreatment/without pretreatment: 40.5%/27.9% |
Chen, M et al., 202024 | ||||